4.5 Article

Thioredoxin reductase: An emerging pharmacologic target for radiosensitization of cancer

期刊

TRANSLATIONAL ONCOLOGY
卷 17, 期 -, 页码 -

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.tranon.2022.101341

关键词

Thioredoxin reductase; Thioredoxin; Redox homeostasis; Radiation

类别

资金

  1. Department of Atomic Energy, Government of India

向作者/读者索取更多资源

This article reviews the potential utility of thioredoxin reductase (TrxR) inhibitors in radiotherapy, highlighting that inhibiting TrxR can enhance the effectiveness of radiation therapy but may also have negative effects on normal cells.
Novel agents are required to increase the radiosensitivity of cancer and improve the outcome of radiotherapy. Thioredoxin (Trx) and thioredoxin reductase (TrxR) reduce the oxidized cysteine thiols in several proteins, which regulate cellular redox, survival, proliferation, DNA synthesis, transcription factor activity and apoptosis. TrxR is essential for maintaining a conducive redox state for tumor growth, survival and resistance to therapy. Therefore, it is an appealing pharmacological target for the radiosensitization of tumors. Ionizing radiation (IR) is known to cause cytotoxicity through ROS, oxidative stress and DNA damage. Inhibition of thioredoxin system augments IR induced oxidative stress and potentiates cytotoxic effects. However, TrxR also regulates several critical cellular processes in normal cells. Here, we highlight the pre-clinical research and pharmacological studies to surmise possible utility of different TrxR inhibitors for radiosensitization. This review provides a succinct perspective on the role of TrxR inhibitors during the radiotherapy of cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据